Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis - Aimo - 2021 - European Journal of Clinical Investigation - Wiley Online Library
New biologic is active against Alzheimer's amyloid plaques - The Pharmaceutical Journal
Journal Club: TREM2 Opens a Rabbit Hole of Questions for Alzheimer's Researchers
Cerebral amyloid angiopathy: an update | Journal of Neurology
PDF) Human lysozyme inhibits the fibrillation of serum amyloid a protein from systemic AA amyloidosis
Amyloid | Taylor & Francis Online
Paper published in Amyloid - labb-group
What is Amyloid? - T. J. Anderson, J. W. Bewen, 1974
Amyloid: Vol 6, No 1
Amyloid Gains Converts in Debate Over Alzheimer's Treatments - WSJ
Mira Tang on LinkedIn: Imaging Amyloid and Tau in the Retina: Current Research and ... : Journal…
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine | DAIC
Infectious origin of Alzheimer's disease: Amyloid beta as a component of brain antimicrobial immunity | PLOS Pathogens
Echocardiography and Amyloidosis Resources
Structural and Dynamic Study of the Transmembrane Domain of the Amyloid Precursor Protein - Nadezhdin - Acta Naturae
Cardiac amyloidosis: An update on diagnosis and treatment | Cleveland Clinic Journal of Medicine
Opportunities for Earlier Diagnosis and Treatment of Cardiac Amyloidosis - Methodist DeBakey Cardiovascular J
Volume 537 Issue 7618, 1 September 2016
Optimal anti-amyloid-beta therapy for Alzheimer's disease via a personalized mathematical model | PLOS Computational Biology
Journal of Stroke
Familial Cerebral Amyloid Angiopathy Due to the Iowa Mutation in an Irish Family | Canadian Journal of Neurological Sciences | Cambridge Core
New dual-phase imaging protocol reduces costs and radiation exposure for cognitively impaired patients
Lyell Jones MD on X: "Are anti-amyloid monoclonals for Alzheimer disease going to overwhelm neurology access? Crush health system finances? Applying trial criteria to a population of MCI/mild-AD patients, <10% of patients
